Smith & Nephew SNATS (NYSE:SNN) Sees Strong Trading Volume – Should You Buy?

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) saw an uptick in trading volume on Tuesday . 824,135 shares changed hands during trading, a decline of 18% from the previous session’s volume of 1,003,425 shares.The stock last traded at $30.52 and had previously closed at $30.53.

Analyst Upgrades and Downgrades

Several research firms recently commented on SNN. Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a report on Monday, May 11th. Canaccord Genuity Group reduced their price target on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research note on Monday, May 11th. Wall Street Zen cut shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. The Goldman Sachs Group restated a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $30.93.

Smith & Nephew SNATS Stock Down 0.4%

The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57. The business’s 50-day moving average price is $31.86 and its 200-day moving average price is $33.11.

Smith & Nephew SNATS (NYSE:SNN) last released its earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The company had revenue of $1.60 billion for the quarter. On average, sell-side analysts forecast that Smith & Nephew SNATS, Inc. will post 2.25 earnings per share for the current fiscal year.

Smith & Nephew SNATS Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Friday, March 27th will be given a dividend of $0.482 per share. This represents a dividend yield of 304.0%. The ex-dividend date of this dividend is Friday, March 27th.

Hedge Funds Weigh In On Smith & Nephew SNATS

Large investors have recently added to or reduced their stakes in the company. Todd Asset Management LLC purchased a new stake in shares of Smith & Nephew SNATS in the third quarter worth $26,319,000. Goldman Sachs Group Inc. boosted its holdings in Smith & Nephew SNATS by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after buying an additional 583,809 shares during the period. Bank of America Corp DE boosted its holdings in Smith & Nephew SNATS by 139.9% in the 3rd quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock worth $35,828,000 after buying an additional 575,666 shares during the period. BNP Paribas Financial Markets increased its stake in Smith & Nephew SNATS by 365.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 644,525 shares of the medical equipment provider’s stock worth $19,742,000 after buying an additional 505,934 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky bought a new stake in Smith & Nephew SNATS during the third quarter valued at about $16,501,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.